BLSM
BlossomHill Therapeutics, Inc. Common Stock (BLSM)
Healthcare • NASDAQ • $16.03-2.14%
- Symbol
- BLSM
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $16.03
- Daily Change
- -2.14%
- Market Cap
- $476.35M
- Trailing P/E
- N/A
- Forward P/E
- N/A
- 52W High
- $17.25
- 52W Low
- $15.25
- Analyst Target
- N/A
- Dividend Yield
- N/A
- Beta
- N/A
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.
Company websiteResearch BLSM on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.